

Unexpected intramolecular cyclization of 4-(2-halophenyl)-1*H*-pyrazolo[3,4-*b*]quinolines: formation of 5- and 7-membered rings from one starter

Krzysztof S. Danel,^{a,*} Anna Wisła,^a and Tomasz Uchacz^b

^a*Department of Chemistry, University of Agriculture, Balicka St. 122, 30-149 Kraków, Poland*

^b*Faculty of Chemistry, Jagiellonian University, Ingardena St. 3, 30-060 Kraków, Poland*

E-mail: rrdanelk@cyf-kr.edu.pl

Abstract

Cyclization of 4-(2-halophenyl)-1*H*-pyrazolo[3,4-*b*]quinolines **3a-b** and **9a-9b** provided two regioisomeric compounds: 6-phenyl-6*H*-5,6,7-triazadibenzo[*f,h*]naphtho[3,2,1-*cd*]azulenes **4,10** and 1,3-diphenyl-3*H*-indeno[1,2,3-*de*]pyrazolo[3,4-*b*]quinolines **2,11**. All of them are considered as new building blocks for optoelectronic materials. The two-step synthesis utilized readily available starting materials.

Keywords: Azafluoranthene, annulation, cyclodehydrohalogenation, 1*H*-pyrazolo[3,4-*b*]quinoline


Introduction

Pyrazolo[3,4-*b*]quinolines (PQs) are known for their antiviral (HSV-1, HSV-2, CMV, VZ and EB) properties,¹ as COX inhibitors,² inhibitors of oncogenic Ras,³ interferon inducing agents,⁴ antimicrobials,⁵ antimalarials,⁶ and potent apoptosis inducers.⁷ PQs also belong to a class of highly fluorescent compounds which emit mostly in the blue spectral range and have been classified as promising materials for optoelectronics.⁸ Attempts have been made to red-shift of their fluorescence spectra,⁹ by changing substituents and introduction of the additional N-atom into the central aromatic ring. In this project we have paid attention to polycyclic aromatic hydrocarbons (PAHs) of a high photoluminescence quantum yields useful for OLEDs.¹⁰ Generally speaking, an increase in the extent of the π -electron system (i.e. degree of conjugation) leads to a shift of the absorption and fluorescence spectra to longer wavelengths and to an increase in the fluorescence quantum yield.¹¹ In the case of PQs the only possibility left to achieve the expected effect is to increase the number of fused rings. In this paper we disclose a practical synthesis of azafluoranthenes and heterocyclic analogues of azulene derived from PQs.

These new heterocycles could be potential building blocks in supramolecular chemistry and luminophores for OLEDs.¹²

Results and Discussion


Since prerequisite PQ **1** could not be simply prepared by the method formerly developed,¹³ which eventually would allow the formation of **2**, its isomeric 4-(2-chlorophenyl)-1,3-diphenyl-1*H*-pyrazolo[3,4-*b*]quinoline **3a** was prepared from 2-chlorobenzaldehyde, 1,3-diphenylpyrazol-5-one and aniline. The isomer was then cyclized according to Clar.¹⁴ Instead of the expected derivative of 3-azafluoranthene **2**, only a seven-membered heterocycle **4** was formed. To confirm our result, we prepared 4-(2-chlorophenyl)-3,7-dimethyl-1-phenyl-1*H*-pyrazolo[3,4-*b*]quinoline **5**. The attempted cyclodehydrohalogenation in **5** on reflux in quinoline/KOH failed. In another approach to facilitate the ring closure we also synthesized **7**, but its cyclization did not yield any traces of **8** (Scheme 1).



Scheme 1


Prolonged reflux of **3a,b** in quinoline did not produce nor **2** or **4**. Therefore, the presence of halogen atom and a strong inorganic base appeared indispensable for the ring closure. Our attempt involving the use of a powerful hindered organic base, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in different solvents,¹⁵ as suggested in the literature did not give appreciable results because of the uncompleted conversion to **4**. Finally, we found that the easiest approach to the synthesis of the regioisomer **2** involved cyclization of 4-(2-bromophenyl)-1,3-diphenyl-1*H*-pyrazolo[3,4-*b*]quinoline **3b** by modified Wegner¹⁶ procedure where $\text{P}(t\text{-Bu})_3$ was used as a ligand instead of $\text{P}(\text{Cy})_3$. This reaction furnished indeno-annelated product **2** with a reasonable yield and only a trace of seven-membered ring system **4** was formed (TLC monitoring). Contrary

to it, heating of **3b** in KOH/quinoline gave exclusively **4**. The same reactions conditions were also examined for **3a**. This delivered a mixture of **2** and **4**, with a low yield. More recently, the group of Scott has proven that even the chlorine atom could be utilized in the intramolecular cyclization using different Pd catalysts.¹⁷ To additionally confirm the site of cyclization, we readily obtained two halo derivatives **9a,b** (Scheme 2). They were treated in the same manner as mentioned above. The characterization of **10** and **11** was achieved by NMR spectroscopy according to the following strategy: i) the spectrum of the regioisomer **11** revealed two doublets



Scheme 2

originating from a free 3-*p*-methoxyphenyl moiety; ii) the analysis of **10** provided evidence for the cross-annulation of the 3-ring. The plausible explanation accounting for the formation of **4** (or **10**) is depicted below (Scheme 3): **3a,b** (**9a,b**) treated with KOH gives a reactive intermediate (*o*-benzyne) **13a**. In the present case **13a** has the possibility of reacting in two different orientations: to close the five-membered ring or to attack the adjacent phenyl moiety. The latter route seems to be more probable to bring the aryne within bonding distance. Thus a diradical **13b** attacks the 3-phenyl ring creating σ bond with hydrogen abstraction. Thus a



Scheme 3

Similar transformation was observed by Cram and coworkers.¹⁸ Indeno[1,2,3]-annelated **2** (or **11**) products are examples of an intramolecular arylation to form the five-membered rings. It is

often considered that such cyclization involves intramolecular electrophilic attack of the arylpalladium(II) moiety **15** on another aromatic ring in the key intermediate.^{15b} In this case the six-membered geometry of the intermediate **16** should facilitate this ring closure and disfavor the formation of seven-membered analogues. On the other hand, the presence of the electron-withdrawing N-atom should make this assumption inconsistent with an electrophilic aromatic-substitution mechanism. Recently, another authors proposed a quite different mechanism proceeding by abstraction of a proton of the arylated ring by the base in a process in which the formation of the metal-carbon bond is concerted with the breaking of the carbon-hydrogen bond.¹⁹ They studied the intramolecular palladium-catalyzed arylation of on a variety of bromobenzyl diaryl methane systems. They found that electron-withdrawing substituents favored this reaction. In our case the 5-position of **3b** is more acidic because of the electronegative N-atom of the pyridine than *ortho*-protons of the proximal phenyl ring at the 3-position. As a result this leads to the nearly exclusive formation of five-membered regioisomers.

Conclusions

In summary, this preliminary report describes two new, efficient synthetic routes to a variety of aromatic structures containing five- and seven-membered rings. The starting materials are cheap, readily available and the compounds can be prepared in 2 steps in most cases without chromatographic separation. The remarkable is the easy formation of seven-membered aromatic ring system which is very rare.²⁰ The latter also can be considered as the example of topological chemical defects spotted in carbon nanotubes (pentagon-heptagon pair).²¹ Both annulated structures can be derived from the same starter. Further studies are under way to expand the scope of the present method, and to use the products for further conversion as well as for the OLED construction.

Experimental Section

1,3-Di(aryl)- and 1-aryl-3-methyl-4-(2-halophenyl)-1*H*-pyrazolo[3,4-*b*]quinolines **3**. General procedure

Equimolar amounts (10 mmol) of aniline, 1,3-diphenylpyrazolin-5-one and 2-halobenzaldehyde were refluxed for 2 h with TLC monitoring in ethylene glycol (20 mL). After cooling the mixture was treated with MeOH. It was refluxed for 30 min, followed by cooling and sonication in a cold water bath for 1 h. The yellow precipitate was collected. Only bromoderivative **3b** was further purified by column chromatography (alumina, toluene) because it was contaminated with a little amount of debrominated product.

4-(2-Chlorophenyl)-1,3-diphenyl-1*H*-pyrazolo[3,4-*b*]quinoline (3a**).** Light yellow solid; yield 1.64 g (38 %); mp = 200–202 °C; UV (MeCN): λ_{max} [nm] = 398 nm; Fluorescence (MeCN) λ_{max}

[nm] = 481; ^1H NMR (300 MHz, CDCl_3) δ 7.06–7.25 (m, 7H), 7.26–7.35 (m, 3H), 7.40 (ddd, 1H, J = 8.7, 6.6, 1.2 Hz), 7.58 (t, 2H, J = 7.5 Hz), 7.64 (ddd, 1H, J = 8.7, 1.5, 0.6 Hz), 7.78 (ddd, 1H, J = 8.7, 6.6, 1.5 Hz), 8.27 (ddd, 1H, J = 8.7, 1.2, 0.6 Hz), 8.62 (d, 2H, J = 9.0 Hz); Anal. Calcd. for $\text{C}_{28}\text{H}_{18}\text{ClN}_3$; C, 77.86; H, 4.20; N, 9.73. Found: C, 77.39; H, 4.56; N, 9.71.

4-(2-Bromophenyl)-1,3-diphenyl-1H-pyrazolo[3,4-*b*]quinoline (3b). Light yellow solid; yield 1.67 g (35%); mp = 204–206 °C; ^1H NMR (300 MHz, CDCl_3) δ 7.06–7.26 (m, 8H), 7.32 (t, 1H, J = 7.5 Hz), 7.39 (ddd, 1H, J = 8.1, 6.6, 1.5 Hz), 7.50–7.53 (m, 1H), 7.57 (t, 2H, J = 7.5 Hz), 7.62 (ddd, 1H, J = 9.0, 1.2, 0.9 Hz), 7.77 (ddd, 1H, J = 9.0, 6.6, 1.5 Hz), 8.26 (ddd, 1H, J = 9.0, 1.2, 0.9 Hz), 8.63 (d, 2H, J = 8.7 Hz); Anal. Calcd. for $\text{C}_{28}\text{H}_{18}\text{BrN}_3$; C, 70.60; H, 3.81; N, 8.82. Found: C, 70.60; H, 4.17; N, 8.97.

4-(2-Chlorophenyl)-3,7-dimethyl-1-phenyl-1H-pyrazolo[3,4-*b*]quinoline (5). This compound was prepared following general procedure for compounds **3** using equimolar (10 mmol) of 3-methylaniline, 1-phenyl-3-methylpyrazolin-5-one and 2-chlorobenzaldehyde. Yellow solid; yield 1.19 g (31%); mp = 147–148 °C; ^1H NMR (300 MHz, CDCl_3) δ 2.13 (s, 3H), 2.57 (s, 3H), 7.20 (dd, 1H, J = 8.7, 1.8 Hz), 7.26 (t, 1H, J = 7.5 Hz), 7.37 (dd, 1H, J = 7.5, 1.8 Hz), 7.42–7.57 (m, 5H), 7.62 (dd, 1H, J = 7.8, 1.2 Hz), 8.00 (t, 1H, J = 0.6 Hz), 8.51 (d, 2H, J = 8.7 Hz); Anal. Calcd. for $\text{C}_{24}\text{H}_{18}\text{ClN}_3$; C, 75.09; H, 4.73; N, 10.95. Found: C, 74.98; H, 4.95; N, 10.93.

6-Butyl-4-(naphthalen-1-yl)-1,3-diphenyl-1H-pyrazolo[3,4-*b*]quinoline (7). This compound was prepared following general procedure for compounds **3** using equimolar (10 mmol) of 4-n-butylaniline, 1,3-diphenylpyrazolin-5-one and 1-naphthaldehyde. Light yellow solid; yield 2.45 g (49%); mp = 152–153 °C; ^1H NMR (300 MHz, CDCl_3) δ 0.80 (t, 3H, J = 7.2 Hz), 1.16–1.28 (m, 2H), 1.44–1.54 (m, 2H), 2.56 (t, 2H, J = 7.5 Hz), 6.74 (t, 2H, J = 7.5 Hz), 6.80–6.84 (m, 2H), 6.95 (t, 1H, J = 7.2 Hz), 7.23–7.34 (m, 6H), 7.39–7.44 (m, 1H), 7.58 (t, 2H, J = 7.5 Hz), 7.64 (dd, 1H, J = 9.0, 1.8 Hz), 7.79–7.83 (m, 2H), 8.21 (d, 1H, J = 8.7 Hz), 8.64 (d, 2H, J = 8.7 Hz); Anal. Calcd. for $\text{C}_{36}\text{H}_{29}\text{N}_3$; C, 85.85; H, 5.80; N, 8.34. Found: C, 85.86; H, 5.89; N, 8.55.

6-Ethyl-4-(2-halophenyl)-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-*b*]quinoline 9a,b. **General procedure**

Equimolar amounts (10 mmol) of 4-ethylaniline, 3-(4-methoxyphenyl)-1-phenylpyrazolin-5-one and 2-halobenzaldehyde were refluxed for 2 h with TLC monitoring in ethylene glycol (20 mL). The mixture was cooled and treated with MeOH. Next it was refluxed for 30 min, followed by cooling and sonication in a cold water bath for 1 h. The yellow precipitate was collected.

4-(2-Chlorophenyl)-6-ethyl-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-*b*]quinoline (9a). Light yellow solid; yield 2.45 g (50%); mp = 149–151 °C; ^1H NMR (300 MHz, CDCl_3) δ 1.24 (t, 3H, J = 7.5 Hz), 2.73 (q, 2H, J = 7.5 Hz), 3.77 (s, 3H, OCH_3), 6.62 (d, 2H, J = 8.7 Hz), 7.13–7.20 (m, 4H), 7.27–7.38 (m, 4H), 7.57 (t, 2H, J = 7.5 Hz), 7.66 (dd, 1H, J = 8.7, 1.8 Hz), 8.18 (d, 1H, J = 9.0 Hz), 8.61 (d, 2H, J = 8.7 Hz); Anal. Calcd. for $\text{C}_{31}\text{H}_{24}\text{ClN}_3\text{O}$; C, 75.99; H, 4.94; N, 8.58. Found: C, 75.63; H, 5.40; N, 8.55.

4-(2-Bromophenyl)-6-ethyl-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-*b*]quinoline (9b). Light yellow solid; yield 2.40 g (45%); mp = 164–165 °C; ^1H NMR (300 MHz, CDCl_3) δ

1.24 (t, 3H, $J = 7.5$ Hz), 2.73 (q, 2H, $J = 7.5$ Hz), 3.76 (s, 3H, OCH₃), 6.62 (d, 2H, $J = 9.0$ Hz), 7.11–7.24 (m, 5H), 7.30 (t, 1H, $J = 7.5$ Hz), 7.34 (dd, 1H, $J = 8.1, 0.6$ Hz), 7.54–7.59 (m, 3H), 7.65 (dd, 1H, $J = 9.0, 2.1$ Hz), 8.18 (d, 1H, $J = 8.7$ Hz), 8.62 (d, 2H, $J = 8.7$ Hz); Anal. Calcd. for C₃₁H₂₄BrN₃O; C, 69.67; H, 4.53; N, 7.86. Found: C, 69.14; H, 4.68; N, 8.07.

Cyclization of 3a and 9a. General procedure

3a (0.50 g, 1.16 mmol), powdered KOH (1.95 g, 34.8 mmol) and quinoline (20 mL) were refluxed for 3–4 h until reaction was completed (TLC, toluene). After cooling, the orange solution was treated with 10% hydrochloric acid (100 mL) and extracted with toluene (2 x 20 mL). The organic phase was washed with saturated aqueous NaCl solution, dried over anhydrous MgSO₄ and evaporated to dryness. The residue was dissolved in chloroform and MeOH was added dropwise on sonication in a cold water bath (1 hour). A precipitate was filtered off.

6-Phenyl-6H-5,6,7-triazadibenzo[*f,h*]naphtho[3,2,1-*cd*]azulene (4). Yellow solid; yield 307 mg (67%); mp = 203–205 °C; IR (KBr) 3100, 1597, 1499, 1461, 1400, 1138, 737, 689 cm⁻¹; UV (MeCN): λ_{max} [nm] = 446 nm; Fluorescence (MeCN) λ_{max} [nm] = 542; ¹H NMR (300 MHz, CDCl₃) δ 7.30 (t, 1H, $J = 7.5$ Hz), 7.38–7.53 (m, 5H), 7.58 (t, 2H, $J = 7.5$ Hz), 7.70–7.75 (m, 2H), 7.80–7.83 (m, 1H), 7.86 (dd, 1H, $J = 8.1, 1.2$ Hz), 8.16 (dd, 1H, $J = 8.4, 0.6$ Hz), 8.31–8.34 (m, 1H), 8.44 (dd, 1H, $J = 8.7, 0.9$ Hz), 8.60 (d, 2H, $J = 8.7$ Hz); ¹³C NMR (75 MHz, CDCl₃) δ 120.31, 120.95, 121.82, 123.69, 125.16, 127.45, 127.54, 127.61, 128.62, 128.88, 129.01, 129.11, 129.52, 129.98, 132.08, 133.47, 134.25, 134.64, 135.40, 138.17, 140.13, 140.68, 142.12, 143.70, 150.49, 150.65; MS (FAB) m/z 396 (M⁺+H); Anal. Calcd. for C₂₈H₁₇N₃; C, 85.04; H, 4.33; N, 10.63. Found: C, 84.92; H, 4.46; N, 10.61.

10-Ethyl-2-methoxy-6-phenyl-6H-5,6,7-triazadibenzo[*f,h*]naphtho[3,2,1-*cd*]azulene (10). Yellow–orange solid; yield 998 mg (71%); mp = 137–139 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.32 (t, 3H, $J = 7.5$ Hz), 2.83 (q, 2H, $J = 7.5$ Hz), 3.91 (s, 3H, OCH₃), 7.03 (dd, 1H, $J = 9.0, 2.7$ Hz), 7.27 (t, 1H, $J = 7.5$ Hz), 7.32 (d, 1H, $J = 2.7$ Hz), 7.41 (td, 1H, $J = 7.8, 1.5$ Hz), 7.48 (td, 1H, $J = 7.5, 1.5$ Hz), 7.55 (t, 2H, $J = 7.5$ Hz), 7.59 (dd, 1H, $J = 9.0, 2.1$ Hz), 7.76 (dd, 1H, $J = 7.8, 1.5$ Hz), 7.89 (dd, 1H, $J = 7.8, 1.5$ Hz), 8.08 (d, 1H, $J = 8.7$ Hz), 8.22 (d, 1H, $J = 0.9$ Hz), 8.23 (d, 1H, $J = 8.7$ Hz), 8.58 (d, 2H, $J = 8.7$ Hz); ¹³C NMR (75 MHz, CDCl₃) δ 15.36, 28.98, 55.46, 114.71, 116.99, 120.09, 120.91, 121.82, 124.82, 124.85, 126.81, 127.64, 128.97, 129.19, 129.43, 131.38, 134.05, 134.93, 135.20, 139.47, 139.68, 140.32, 140.50, 141.22, 143.64, 149.42, 150.50, 159.89; Anal. Calcd. for C₃₁H₂₃N₃O; C, 82.10; H, 5.11; N, 9.26. Found: C, 82.00; H, 5.49; N, 9.24.

Cyclization of 3b and 9b. General procedure

3b (476 mg, 1 mmol), Pd₂(dba)₃ (25 mg, 0.024 mmol, 2.4% mol) and DBU (0.30 mL) were placed in a 25 mL round-bottomed flask. The flask was capped with a rubber septum and dry DMF (15 mL) was added through a syringe. The mixture was flushed with argon for 30 min and P(*t*-Bu)₃ in toluene (19.4 mg, 0.096 mmol, 0.12 mL) was added in one portion. The mixture was stirred for another 10 min at room temperature then the yellow solution was 3 h stirred in an oil

bath at 130°C until starting material disappeared. After cooling, the deep brown solution was poured into water (25 mL). The mixture was extracted with toluene (2 x 25 mL). The organic phase was washed with saturated aqueous NaCl solution and dried over anhydrous MgSO₄. After evaporation, the residue was treated with chloroform (5 mL) and MeOH was added dropwise on sonication in a cold water bath. The precipitate was filtered off.

1,3-Diphenyl-3H-indeno[1,2,3-*de*]pyrazolo[3,4-*b*]quinoline (2). Orange crystals; yield 285 mg (72%); mp = 212–214 °C; IR (KBr) 3111, 1599, 1499, 1447, 1403, 1387, 753, 689 cm⁻¹; UV (MeCN): λ_{max} [nm] = 437 nm; Fluorescence (MeCN) λ_{max} [nm] = 550; ¹H NMR (300 MHz, CDCl₃) δ 6.90 (dt, 1H, *J* = 7.5, 0.6 Hz), 7.03 (td, 1H, *J* = 7.5, 1.2 Hz), 7.31 (dd, 1H, *J* = 7.5, 1.2 Hz), 7.34 (t, 1H, *J* = 7.2 Hz), 7.55–7.63 (m, 5H), 7.72 (dd, 2H, *J* = 4.8, 1.2 Hz), 7.75–7.83 (m, 3H), 7.95–8.00 (m, 1H), 8.53 (d, 2H, *J* = 8.7 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 112.81, 118.92, 121.61, 121.65, 123.98, 125.82, 127.72, 127.93, 128.27, 128.54, 129.01, 129.37, 129.90, 130.22, 132.30, 133.90, 137.35, 138.34, 139.82, 139.87, 140.98, 144.79, 145.90, 153.07; MS (FAB) *m/z* 396 (M⁺+H); Anal. Calcd. for C₂₈H₁₇N₃: C, 85.04; H, 4.33; N, 10.63; found: C, 85.11; H, 4.37; N, 10.48.

7-Ethyl-1-(4-methoxyphenyl)-3-phenyl-3H-indeno[1,2,3-*de*]pyrazolo[3,4-*b*]quinoline (11). Light yellow crystals; yield 170 mg (75%); mp = 200–203 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (t, 3H, *J* = 7.5 Hz), 3.21 (q, 2H, *J* = 7.5 Hz), 3.96 (s, 3H, OCH₃), 7.08 (dd, 1H, *J* = 1.5, 0.9 Hz), 7.10 (d, 1H, *J* = 0.6 Hz), 7.13 (d, 2H, *J* = 8.7 Hz), 7.30–7.42 (m, 2H), 7.57 (t, 2H, *J* = 7.5 Hz), 7.60 (d, 1H, *J* = 8.7 Hz), 7.73 (d, 2H, *J* = 8.7 Hz), 7.90 (d, 1H, *J* = 7.8 Hz), 7.96 (d, 1H, *J* = 9.0 Hz), 8.54 (d, 2H, *J* = 8.7 Hz); ¹³C NMR (75 MHz, CDCl₃) δ ; 14.84, 26.74, 55.50, 112.50, 113.97, 121.51, 123.73, 124.18, 125.59, 126.52, 126.93, 128.03, 128.51, 128.97, 129.78, 131.50, 133.85, 135.17, 137.49, 138.82, 139.59, 139.99, 141.06, 143.73, 145.57, 152.69, 160.56; Anal. Calcd. for C₃₁H₂₃N₃O: C, 82.10; H, 5.11; N, 9.26. Found: C, 82.00; H, 5.27; N, 9.34.

Acknowledgements

Dr. Marek Kasprowicz (Dept. of Physics, University of Agriculture) is acknowledged for recording IR spectra.

References

1. Afonso, A.; Kelly, J. M.; Chackalamannil, S. U.S. Patent 5,506,236, 1996; *Chem. Abstr.* **1996**, 125, 33629q.
2. Uchikawa, O.; Mitsui, K.; Asakawa, A.; Morimoto, S.; Yamamoto, M.; Kimura, H.; Moriya, T.; Mizuno, M. U.S. Patent 6,949,648, 2005; *Chem. Abstr.* **2005**, 143, 306450.
3. Wolin, R.; Wang, D.; Kelly, J.; Afonso, A.; James, L.; Kirschmeier, P.; McPhail, A. T. *Bioorg. Med. Chem. Lett.* **1996**, 6, 195.

4. Crenshaw, R. R.; Luke, G. M.; Siminoff, P. *J. Med. Chem.* **1976**, *19*, 262.
5. El-Sayed, O. A.; Aboul-Enein, H. Y. *Arch. Pharm. Pharm. Med. Chem.* **2001**, *334*, 117.
6. Stein, R. G.; Biel, J. H.; Singh, T. *J. Med. Chem.* **1970**, *13*, 153.
7. Zhang, H. Z.; Claassen, G.; Crogran-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S. X. *Bioorg. Med. Chem.* **2008**, *16*, 222.
8. (a) Danel, A.; He, Z.; Milburn, G. H. W.; Tomasik, P. *J. Mater. Chem.* **1999**, *9*, 339. (b) Tao, Y. T.; Balasubramaniam, E.; Danel, A.; Wisla, A.; Tomasik, P. *J. Mater. Chem.* **2001**, *11*, 768. (c) Fuks-Janczarek, I.; Gondek, E.; Kityk, I. V.; Danel, K.; Krzemińska, L.; Sanetra, J.; Kwiecień, B. *Spectrochim. Acta, Part A* **2006**, *63*, 320.
9. (a) Tao, J. T.; Balasubramaniam, E.; Danel, A.; Jarosz, B.; Tomasik, P. *Appl. Phys. Lett.* **2000**, *77*, 1575. (b) Gondek, E.; Kityk, I. V.; Danel, A.; Wisla, A.; Pokladko, M.; Sanetra, J.; Sahraoui, B. *Mat. Lett.* **2006**, *60*, 3301.
10. (a) Mi, B. X.; Gao, Z. Q.; Lee, C. S.; Kwong, H. L.; Wang, N. B.; Lee, S. T. *J. Mater. Chem.* **2001**, *11*, 2244. (b) Mi, B. X.; Gao, Z. Q.; Liu, M. W.; Chan, K. Y.; Kwong, H. L.; Wong, N. B.; Lee, C. S.; Hung, L. S.; Lee, S. T. *J. Mater. Chem.* **2002**, *12*, 1307.
11. Valeur, B. *Molecular Fluorescence: Principles and Applications*; Wiley: New York, 2001; pp 54–65.
12. (a) De Backer, S.; Prinzie, Y.; Verheijen, W.; Smet, M.; Desmedt, K.; Dehaen, W.; De Schryver, F. *C. J. Phys. Chem. A* **1998**, *102*, 5451. (b) Smet, M.; Dehaen, W. *Molecules* **2000**, *5*, 620. (c) Chen, J.-P. U.S. Patent 20040101711, 2004; *Chem. Abstr.* **2004**, *141*, 14229.
13. (a) Chaczatryan, K.; Chaczatryan, G.; Danel, A.; Tomasik, P. *ARKIVOC* **2001**, (vi), 63. (b) Danel, A.; Chaczatryan, K.; Tomasik, P. *ARKIVOC* **2000**, (i), 51.
14. (a) Clar, E.; Kelly, W.; Wright, J. W. *J. Chem. Soc.* **1954**, 1108. (b) Clar, E.; Willicks, W. *J. Chem. Soc.* **1958**, 942. (c) Smet, M.; Shukla, R.; Fülöp, L.; Dehaen, W. *Eur. J. Org. Chem.* **1998**, *12*, 2769.
15. (a) Wang, L.; Shevlin, P. B. *Org. Lett.* **2000**, *2*, 3703. (b) Echavarren, A. M.; Gómez-Lor, B.; González, J. J.; de Frutos, Ó. *Synlett* **2003**, *5*, 585. (c) Cheng, X. H.; Höger, S.; Fenske, D. *Org. Lett.* **2003**, *5*, 2587.
16. Wegner, H. A.; Scott, L. T.; de Meijere, A. *J. Org. Chem.* **2003**, *68*, 883.
17. Jackson, E. A.; Steinberg, B. D.; Bancu, M.; Wakamiya, A.; Scott, L. T. *J. Am. Chem. Soc.* **2007**, *129*, 484.
18. (a) Warmuth, R. *Chem. Commun.* **1998**, *1*, 59. (b) Beno, B. R.; Sheu, C.; Houk, K. N.; Warmuth, R.; Cram, D. J. *Chem. Commun.* **1998**, *3*, 301.
19. Pascual, S.; de Mendoza, P.; Echavarren, A. M. *Org. Biol. Chem.* **2007**, *5*, 2727.
20. Kaoudi, T.; Quiclet-Sire, B.; Seguin, S.; Zard, S. Z. *Angew. Chem. Int. Ed.* **2000**, *39*, 731.
21. (a) Crespi, V. H.; Cohen, M. L.; Louie, S. G. S.; Zettl, A. K. U. S. Patent 6,835,952, 2004; *Chem. Abstr.* **2003**, *138*, 264103. (b) Nasibulin, A. G.; Queipo, P.; Shandakov, S. D.; Brown, D. P.; Jiang, H.; Pikhitsa, P. V.; Tolochko, O. V.; Kauppinen, E. I. *J. Nanosci. Nanotechnol.* **2006**, *6*, 1233. (c) Ponomareva, I.; Chernozatonskii, L. A.; Andriotis, A. N.; Menon, M. N. *J. Phys.* **2003**, *5*, 119.1. (d) Bronstein, H. E.; Scott, L. T. *J. Org. Chem.* **2008**, *73*, 88.